Type 2 diabetes mellitus (T2DM) continues to impose a substantial clinical and economic burden, particularly in India, where long-term adherence to daily therapy remains a challenge. Simplified dosing strategies may influence treatment patterns in routine practice. A multicentre, questionnaire-based survey published in the International Journal of Clinical Metabolism and Diabetes assessed physician perceptions and prescribing patterns related to trelagliptin, a once-weekly dipeptidyl peptidase-4 inhibitor (DPP-4i), in the management of T2DM.

The survey included 71 medical professionals from diverse specialties across India. The structured questionnaire captured information on clinical experience, patient profiles, and perceptions related to glycemic control, adherence, tolerability, safety, cost-effectiveness, and prescribing considerations. Descriptive statistical methods were used to summarize responses.

Most respondents were consultant physicians (64.79%), followed by diabetologists or endocrinologists (18.31%) and other specialists (16.90%). Patients with poor adherence to daily medications were commonly identified as appropriate candidates for trelagliptin (70.42%). A high proportion of clinicians reported perceived improvements in adherence (94.37%) and glycemic control (90.14%). Perceived advantages also included improved tolerability (97.18%), greater cost-effectiveness (66.20%), and reduced pill burden (64.79%).

These findings reflect clinician-reported experience, indicating that once-weekly trelagliptin may support adherence and simplify treatment in routine care settings.